Why Peptide Dosing in Studies Rarely Matches Marketing
The doses in the research and the doses on the label are often worlds apart.
When a peptide gets cited as “studied” and “promising,” it’s easy to assume the dose you’d actually use lines up with the dose in the research. Frequently it doesn’t. The number on a vial or in a forum protocol and the number in the underlying paper can be worlds apart — and the difference quietly undermines a lot of confident claims.
Where the gap comes from
There are a few recurring reasons the doses diverge, and most of them point the same direction: the marketing dose is rarely the one that was actually tested in people.
- Animal-to-human translation. Many peptide claims trace back to rodent studies, and converting an animal dose to a human one is not simple body-weight math. The standard pharmacology method scales by body surface area: human equivalent dose (mg/kg) = animal dose × (animal Km / human Km). Because the mouse Km is 3 and the human Km is 37, a mouse mg/kg dose is divided by roughly 12.3 to estimate the human equivalent. Multiplying straight across by body weight badly overestimates the human dose — and casual protocols often skip the math entirely.
- Different routes and formulations. A dose that worked as a controlled infusion or a specific injectable in a trial may bear little relation to a self-administered version sold online.
- Cherry-picked references. A product may cite a study to borrow its credibility while using a completely different amount, schedule, or even a related-but-distinct molecule.
The blunt version: “there’s research on this peptide” and “the dose I’m taking is supported by research” are two different statements, and the second is far less often true.
What to actually check
If you’re evaluating a claim, look at the original study’s species, route of administration, exact dose, and duration — then apply the body-surface-area conversion before comparing to what’s being sold. The FDA’s 2005 guidance on safe starting doses uses exactly this allometric approach for a reason: naive mg/kg scaling is unreliable. The mismatch is usually obvious once you do the math.
The takeaway
Citation of a study is not the same as replication of its dosing. With peptides especially, marketing tends to inherit the optimism of the research while quietly abandoning its specifics — including the species-correction step that often shrinks a headline animal dose by an order of magnitude. When the label and the literature don’t match, the literature isn’t really backing the label, and that gap is where overstatement lives.